During the last session, Prime Medicine Inc (NASDAQ:PRME)’s traded shares were 0.53 million, with the beta value of the company hitting 2.09. At the end of the trading day, the stock’s price was $4.03, reflecting an intraday gain of 3.87% or $0.15. The 52-week high for the PRME share is $9.86, that puts it down -144.67 from that peak though still a striking 18.61% gain since the share price plummeted to a 52-week low of $3.28. The company’s market capitalization is $483.72M, and the average intraday trading volume over the past 10 days was 1.05 million shares, and the average trade volume was 1.41 million shares over the past three months.
Prime Medicine Inc (PRME) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. PRME has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.44.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Prime Medicine Inc (NASDAQ:PRME) trade information
The stock spiked 3.87% in intraday trading to $4.03, hitting a weekly high. The stock’s 5-day price performance is 0.00%, and it has moved by 18.18% in 30 days. Based on these gigs, the overall price performance for the year is -37.23%. The short interest in Prime Medicine Inc (NASDAQ:PRME) is 17.64 million shares and it means that shorts have 6.41 day(s) to cover.
The consensus price target of analysts on Wall Street is $17, which implies an increase of 76.29% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $23 respectively. As a result, PRME is trading at a discount of -470.72% off the target high and -197.77% off the low.
Prime Medicine Inc (PRME) estimates and forecasts
Statistics show that Prime Medicine Inc has underperformed its competitors in share price, compared to the industry in which it operates. Prime Medicine Inc (PRME) shares have gone down -27.91% during the last six months, with a year-to-date growth rate less than the industry average at 13.79% against 17.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 20.00% this quarter and then jump 37.50% in the quarter after that.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 7.83M as predicted by 10 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 400k by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -193.88%. While earnings are projected to return 24.49% in 2024.
PRME Dividends
Prime Medicine Inc is due to release its next quarterly earnings on 2024-Aug-08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
Prime Medicine Inc insiders own 26.12% of total outstanding shares while institutional holders control 67.77%, with the float percentage being 91.74%.
